Slide 1: Revolutionizing the Delivery of Rescue Treatments
REVOLUTIONIZING THE DELIVERY OF RESCUE TREATMENTS POWERED BY THE INNOVATIVE ZENEO ® NEEDLE - FREE AUTOINJECTOR TECHNOLOGY MARCH 2026 MARCH 2026 1
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. By receiving and using this presentation and/or accepting a copy of this prese nta tion, you agree to be bound by the following limitations and conditions and, in particular, will be taken to have represented, warranted and undertaken that yo
Slide 3: The Crossject Value Drivers
THE CROSSJECT VALUE DRIVERS Innovative needle - free autoinjector drug delivery platform with broad applications across multiple APIs, over €200M total invested to date. ZENEO® Midazolam needle - free autoinjector first to market under EUA with NDA to follow. Revenue generating with $30M of $43M dev
Slide 4: Summary
SUMMARY 1 PRESENTATION OF CROSSJECT AND ZENEO® p.5 1 PRESENTATION OF CROSSJECT AND p.5 ZENEO® 2 DEVELOPMENT PIPELINE p.15 2 DEVELOPMENT PIPELINE p.15 ZOOM: ZEPIZURE®, THE NEW PARADIGM FOR EPILEPSY RESCUE INJECTIONS ZOOM: ZEPIZURE®, THE NEW PARADIGM 3 p.19 3 FOR EPILEPSY RESCUE INJECTIONS p.19 4 COMM
Slide 5: Discover ZENEO, a Unique Autoinjector Technology
DISCOVER ZENEO ® , A UNIQUE AUTOINJECTOR TECHNOLOGY Proprietary technology Multiple medical applications Internal manufacturing Full dose delivery in 1/10 of a second, needle - free Allows emergency use by non - healthcare professionals Shortened and de - risked 505 (B)2 regulatory pathway MARCH 202
Slide 6: How Does ZENEO Work?
HOW DOES ZENEO ® WORK ? Instant complete injection in 1/10th of a second Gas generator 1 ZENEO® pressed on the skin Piston Triggering mechanism Triggering mechanism 2 As soon as the device is pressed against the skin, the striker releases the pressure... Nozzle with micro - holes Gas generator 3 Pyr
Slide 7: We Are Not Pure Medtech, but Rather Pharma, Based on Medtech
WE ARE NOT PURE MEDTECH, BUT RATHER PHARMA, BASED ON MEDTECH CROSSJECT develops and manufactures a unique proprietary combined product (medical device + drug) Medical device: ZENEO® can be adapted to ZENEO ® : a unique and innovative autoinjector dozens of molecules and medical applications (epileps
Slide 8: ZENEO Is the Solution for Emergency Use by Non-Healthcare Professionals
ZENEO ® IS THE SOLUTION FOR EMERGENCY USE BY NON - HEALTHCARE PROFESSIONALS Emergency Situations Outside of Hospital An Patient Patient or Patient is keeps Should the bystander emergency … contacts diagnosed the rescue patient injects rescue medical emergency to be prone treatment experience the app
Slide 9: Intramuscular Is the Standard for Emergency Administration
INTRAMUSCULAR IS THE STANDARD FOR EMERGENCY ADMINISTRATION Autoinjectors ( with needles ) Intranasal High failure rate ( 61% to 84%) . High variability ( may cause unpredictable drug concentrations in the blood). 50% of patients suffer from needle phobia . Needles are often too short for a true Perf
Slide 10: ZENEO Autoinjector: Designed and Engineered to Save Lives
ZENEO ® AUTOINJECTOR: DESIGNED AND ENGINEERED TO SAVE LIVES Robust testing made across the full spectrum of populations in stressful and realistic situations - adults, children, trained, untrained, mass attack*… - Situations simulated with volunteers ( human factors non - clinical testing ) 1300 US
Slide 11: We Manufacture ZENEO
WE MANUFACTURE ZENEO® We manufacture ZENEO® ready to fill 1 The mechanical actuator 2 The sterile drug container (ZENEO® Nest) Including key proprietary know - how: Tempering enables glass tubes to withstand pressures of up to 350 bar Each ZENEO® equipped with its own micro gas generator Drug ingred
Slide 12: > €200M Raised Since 2001, First Product Sales in 2026
> € 200M RAISED SINCE 2001, FIRST PRODUCT SALES IN 2026 2022 Clinical ZENEO ® efficiency 2005 for Intramuscular injection Successful first 2014 U.S. BARDA agreement clinical trial with signed up to $165M* a flu vaccine Euronext IPO 2026 First delivery to BARDA (U.S. Dept of Health) 2010 2001 ZENEO ®
Slide 13: Crossject: An Emerging Specialty Pharma
CROSSJECT: AN EMERGING SPECIALTY PHARMA 110 employees in France ZEPIZURE ® to be distributed and the U.S . by CROSSJECT in the US Listed on Euronext Growth market Paris - 2014 : ALCJ ZEPIZURE® FDA approval Multiple partner validations expected early 2026 including BARDA* collaboration 2 additional m
Slide 14: Shareholding Structure as of 31 December 2025
SHAREHOLDING STRUCTURE** AS OF 2025 DECEMBER 31TH Significant liquidity on Euronext Growth (>€500k per day, 65 - day average) Shareholders ** (as of 31 December 2025) *** 21,66% Float Gemmes Venture SNPE : 1,24% IDEB : 0,29% AutoControl : 0,13% SNPE Other nominatives: 3,58% Float : 73,11% IDEB AutoC
Slide 15: Development Pipeline
DEVELOPMENT PIPELINE MARCH 2026 15
Slide 16: Three Launch ZENEO Applications in Active Development
THREE LAUNCH ZENEO ® APPLICATIONS IN ACTIVE DEVELOPMENT ZENEO ® autoinjector is an i ntuitive , effective and safe device , designed for emergency situations outside of hospital Epileptic Seizures – • Global market for epilepsy drugs ~$10B ZEPIZURE® Midazolam • US market for epilepsy drugs ~$4B Firs
Slide 17: Strategic Commercial Partnerships: Maximizing Global Reach & Value
STRATEGIC COMMERCIAL PARTNERSHIPS : MAXIMIZING GLOBAL REACH & VALUE Existing Licensing Partnerships North America : ETON Pharmaceuticals Crossject S.A. Zeneo - Hydrocortisone (Adrenal crisis indication) Out - Licensing Strategy Europe: Unnamed EUR Partner Zeneo - Midazolam (status Epileptics, seizur
Slide 18: Initial Peak Sales Over €1 Billion
INITIAL PEAK SALES OVER €1 BILLION €607M ZENEO ® Adrenaline ZEPIZURE ® €251M ZENEO ® Hydrocortisone €209M € >1 billion Worldwide peak sales to be shared between CROSSJECT and our distributors . CROSSJECT estimates for target sales volume MARCH 2026 18
Slide 19: Zoom: The New Paradigm for Epilepsy Rescue Injections
ZOOM: THE NEW PARADIGM FOR EPILEPSY RESCUE INJECTIONS ZEPIZURE ® = ZENEO ® + EPILEPTIC DRUG MARCH 2026 19
Slide 20: ZEPIZURE Works Against Poisoning and Epilepsy
ZEPIZURE ® WORKS AGAINST POISONING AND EPILEPSY, EVEN SEVERE EPILEPSY CRISIS EPILEPSY POISONING Life Threatening and Costly Health Economics National Health Priority in the U.S. • More than 5000 U.S. deaths per year related to epilepsy • Critical need for inclusion in the U.S. Strategic ( seizure >
Slide 21: ZEPIZURE: De-risked Commercialization Plan for the U.S. (2026-2027)
ZEPIZURE ® : DE - RISKED COMMERCIALIZATION PLAN FOR THE U.S (2026 - 2027) EUA = Emergency Use Authorization : process dedicated to national emergencies NDA = New Drug Application, 502 (B) 2: FDA standard process for commercialization REVENUE LAUNCH WITH Step 1: after EUA to be filed by BARDA on beha
Slide 22: BARDA Awarded Contract of Up to $165M
BARDA AWARDED CONTRACT OF UP TO $165M (43M + 60M + 59M + 3M) • Contract no : 75A50122 C 00031 with the Department of Health and Human Services ; Administration for Strategic Preparedness and Response ; Biomedical Advanced Research and Development Authority ( BARDA ) • Biomedical Advanced Research &
Slide 23: The ZEPIZURE US Opportunity: Delivery Is the Difference
THE ZEPIZURE ® US OPPORTUNITY: DELIVERY IS THE DIFFERENCE! ZEPIZURE ® Commercial Value Proposition The First Pre - filled, Single - Use, Simple & Easy, Needle - Free Autoinjector, that instantly delivers a full - dose of Midazolam in 1/10 th of a second for Status Epilepticus MARKET CONDITIONS COMPE
Slide 24: Commercial Horizon: The Road to Market
COMMERCIAL HORIZON: THE ROAD TO MARKET MARCH 2026 24
Slide 25: Emergency Treatment / Lives Saving Pipeline Growth
EMERGENCY TREATMENT / LIVES SAVING PIPELINE GROWTH New, enhanced solutions leveraging current gold 2026 2027 2028 Partner / standard treatments sponsor ZEPIZURE ® - Epilepsy / Poisoning (Midazolam) U.S. - Emergency Use EUA Authorization (EUA) U.S. - Status Epilepticus (SE) NDA 1 U.S. - Prolonged Sei
Slide 26: Emergency Treatment / Lives Saving Future Indication Powered by ZENEO
EMERGENCY TREATMENT / LIVES SAVING FUTURE INDICATION POWERED BY ZENEO® New, Enhanced Solutions Target leveraging current Gold Disease Category , Regulatory Target NDA Commercial Standard TREATMENTS Possible Indications Pathway Filing Year Launch Year ZEPIZURE ® Neurology - Epilepsy EUA, NDA 505(b)(2
Slide 27: Financial Results for FYE 31 December 2025
FINANCIAL RESULTS FOR FYE 31 DECEMBER 2025 MARCH 2026 27
Slide 28: Financial Results for FYE December 2025
FINANCIAL RESULTS FOR FYE 31 DECEMBER 2025 2025 vs. 2024 – simplified i view Operating income Operating result Net result Financial result €14.9m €(11.6)m €(10.4)m €(1.6)m +12.2% vs. 2024 +1,4 M€ vs 2024 +€2.4m improvement vs. 2024 vs. €(1.4)m in 2024 €m 2025 2024 Δ KEY COMMENTS Revenue growth was m
Slide 29: Balance Sheet – Assets
BALANCE SHEET – ASSETS 31 December 2025 vs. 31 December 2024 ASSET - SIDE READING €m 2025 2024 Δ The asset base continues to reflect sustained investment in R&D net 8.1 9.6 (1.5) development and industrial readiness. Work in progress 4.5 2.9 +1.6 R&D net declines mechanically through amortisation ,
Slide 30: Balance Sheet – Liabilities & Equity
BALANCE SHEET – LIABILITIES & EQUITY 31 December 2025 vs. 31 December 2024 Bank debt Convertible debt Other bonds €10.2m €4.6m €5.0m €m 2025 2024 Δ €2.7m repaid in 2025 down from €5.5m new financing layer Equity (4.9) (2.7) (2.2) Liability - side reading Convertible bonds 4.6 5.5 (0.9) The debt prof
Slide 31: Cash Position & Funding Discipline
CASH POSITION & FUNDING DISCIPLINE FYE 2025 – liquidity view Cash at year - end CIR receivable Liquidity base Bank debt repaid €5.1m €2.8m €7.9m €2.7m 31 Dec 2025 2025 tax credit cash + CIR during 2025 CASH MESSAGE CFO TAKE - OUT Cash proved resilient once the CIR receivable is included. 2025 was a
Slide 32: Key Message – 2025 Financial Improvement
KEY MESSAGE – 2025 FINANCIAL IMPROVEMENT P&L Statement Operating income increased to €14.9m, up 12.2% year on year. Key metric 2025 2024 Operating result improved to €(11.6)m and net result improved to Operating income 14.9 13.3 €(10.4)m. Operating result (11.6) (13.0) The improvement was achieved w
Slide 33: Key Message – Balance Sheet & Debt Evolution
KEY MESSAGE – BALANCE SHEET & DEBT EVOLUTION Balance-sheet Crossject actively managed its balance sheet in 2025. Bank debt was reduced by €2.7m, from €12.9m to €10.2m. Convertible debt also declined, while additional bond financing was arranged to support the development agenda. The company therefor
Slide 34: Key Message – Liquidity & Funding Priorities
KEY MESSAGE – LIQUIDITY & FUNDING PRIORITIES Funding remains a priority Year - end cash stood at €5.1m, complemented by €2.8m of 2025 R&D tax credit receivable. Liquidity is therefore best read as €7.9m of cash and near - cash resources. The company continues to explore financing options to support
Slide 35: Our Lives Saving Products Have Competitive Advantages
OUR LIVES SAVING PRODUCTS HAVE COMPETITIVE ADVANTAGES THAT ARE UNMATCHED BY CURRENT TREATMENT SOLUTIONS ~€200M invested The best solution to Cumulative market save lives. opportunitues with €30 M billed since 2013 Proven medical estimated peak sales of over Market cap ~ €120M treatments leverage €1
Slide 36: Crossject USA, Crossject SA Global HQ, Investor Relations
CROSSJECT USA CROSSJECT SA Global HQ INVESTOR RELATION CROSSJECT USA, Inc. investors@crossject.com 6, rue Pauline Kergomard 1900 W Kirkwood Blvd. info@crossject.com 21000 DIJON - FRANCE Suite 2500A - 316 crossject.com Southlake , Texas 76092 MARCH 2026 36
Slide 37: Appendix
APPENDIX MARCH 2026 37
Slide 38: Highly Experienced Senior Leadership Team
HIGHLY EXPERIENCED SENIOR LEADERSHIP TEAM Isabelle LIEBSCHUTZ Olivier LACOMBE Quality & Regulatory Director Pharma Development Director Member of the executive Board 21 years experience 26 years experience Fournier labs, Abbott, Solvay, Fournier labs , Solvay, Plasto Inventiva Santé Joined in 2021 J
Slide 39: ZENEO: Unique and Innovative Autoinjector Technology Platform
ZENEO ® : UNIQUE AND INNOVATIVE AUTOINJECTOR TECHNOLOGY PLATFORM ZENEO ® Autoinjector Instantly Delivers a Full - Dose of Drug to IM Depth in < 1/10th of a second! Instant One Quick - Click Full - Dose Delivery Versatility drug, depth, viscosity… User - Intuitive, mobility friendly Strong IP 2038 pa
Slide 40: Clinically Proven Effectiveness
CLINICALLY PROVEN EFFECTIVENESS ZENEO® is equivalent to a 12 clinical studies needle up to 3 cm for intra - muscular use Clinically validated efficacy of intramuscular and subcutaneous ZENEO® works through clothing injection Similar side effect compared to Very low variability in dose delivery tradi
Slide 41: Focus on ZEPIZURE Use Validation in Real Emergency Situation
FOCUS ON ZEPIZURE ® USE VALIDATION IN REAL EMERGENCY SITUATION Use in case of an epileptic seizure Use in case of poisoning following a disaster A wide diversity of situations and potential users including professionals , children from 8 years old , BARDA* under stressful and trained, untrained, adu
Slide 42: Crossject Intellectual Property Portfolio
CROSSJECT INTELLECTUAL PROPERTY PORTFOLIO Strong global IP protecting the ZENEO® technology and multiple drug formulations 25+Patent 90+ Global Patents IP Lifecycle to Coverage in Major Families Applications 2042 + Pharmaceutical Markets Formulation patents : Midazolam, Epinephrine, Hydrocortisone a
Slide 43: Adaptability of ZENEO Platform Offers Broad Commercial Opportunities
ADAPTABILITY OF ZENEO ® PLATFORM OFFERS BROAD COMMERCIAL OPPORTUNITIES Adaptable Versatile Streamlined Reliable Eligible for regulatory Adjustable penetration Leverages the same Meets FDA programs with shorter pressure, drug delivery, components and regulatory approval timelines and and allows for v
Slide 44: ZENEO: Proven and Recognized Ease of Use by Multiple Awards
ZENEO® : PROVEN AND RECOGNIZED EASE OF USE BY MULTIPLE AWARDS MARCH 2026 44
Slide 45: The US Market Opportunity - Delivery Is the Difference
THE US MARKET OPPORTUNITY - DELIVERY IS THE DIFFERENCE! ® : 505(b)(2) HYDROCORTISONE + ZENEO ® : 505(b)(2) EPINEPHRINE + ZENEO Value Proposition Value Proposition The First Pre - filled, Single - Use, Simple & Easy, Needle - Free The First Pre - filled, Single - Use, Simple & Easy, Needle - Free Aut
Slide 46: ZEPIZURE – Near Completion of the FDA EUA Process
ZEPIZURE® – NEAR COMPLETION OF THE FDA EUA PROCESS NDA 505(b)(2) Agreement on the EUA dossier content Status Epilepticus & Poisoning (clinical studies, CMC minimal requirements) Presentation of ZENEO ® functions, manufacturing process, quality and EUA controls Dossier 6 months stability data from 1s
Slide 47: A Versatile Technology: Civilian and Military
A VERSATILE TECHNOLOGY: CIVILIAN AND MILITARY Previous exchanges with national Selected injectable drugs for potential defense innovation ecosystem public safety use RAPID Program (Support Scheme for Dual - Use Drug Indication / Use Innovation) Atropine → CBRN (Chemical, Biological, Radiological, Nu
Slide 48: Diversified Financial Resources
DIVERSIFIED FINANCIAL RESOURCES + EACH YEAR Q4 2024 Research tax credit Reserved capital increase ($2M - $3M) (French 2023 with first U.S. investors legislation) Q2 2024 private placement (€7.2M Bank debts + up to €10.2M from (€12M + €2M) Successful warrants exercise) rights offering of €8M H2 2025
Slide 49: Strong M&A Opportunity: 5x Exit
STRONG M&A OPPORTUNITY : 5X EXIT GREAT EXAMPLES OF VALUE CREATION IN OUR SECTOR (OLD GENERATION TECHNOLOGIES) $180M $110M $70M annual sales annual sales annual sales Exit $960 million $450 million $310 million Benchmark = Exit 4x to 5x sales volume MARCH 2026 49
Slide 50: Significant Upside Potential as FDA Filing Is Approaching
SIGNIFICANT UPSIDE POTENTIAL AS FDA FILING IS APPROACHING Switch to new CDMO announced Potential short term upside Filing postponed as we are close to filing 2024 2024 2024 2024 2024 2024 2025 2025 2025 2025 2025 2025 MARCH 2026 50
Slide 51: Manufacturing Highlights
MANUFACTURING HIGHLIGHTS MARCH 2026 51
Slide 52: Streamlined Manufacturing Process
STREAMLINED MANUFACTURING PROCESS ZENEO ® Nest ISO 13485 GMP DEPYROGENATION & STERILIZATION (CROSSJECT) COMPOUNDING & ASEPTIC FILLING GLASS FORMING TOUGHENING (CMO) TUBINGS (NIPRO) (CROSSJECT ) (SCHOTT) Component s FINAL ASSEMBLY s (CMO) GAZ ACTUATOR GENERATOR ASSEMBLY ASSEMBLY (CROSSJECT) (CROSSJEC
Slide 53: Crossject Key Manufacturing Equipment
CROSSJECT KEY MANUFACTORING EQUIPMENT Tubes Forming Thermal Toughening of Tubes Gas Generator Manufacturing Dimensional Control of Components MARCH 2026 53 Tubes Forming
Slide 54: Crossject Key Manufacturing Equipment
CROSSJECT KEY MANUFACTORING EQUIPMENT Final Quality Control Mechanical Resistance of Tubes Actuators Assembly Depyrogenation of tubes MARCH 2026 54
Slide 55: ZENEO Nest: Crossject's Latest Manufacturing Innovation
ZENEO ® NEST : CROSSJECT’S LATEST MANUFACTURING INNOVATION ZENEO ® Nest enables scalable and sovereign deployment through CDMOs ZENEO® Nest allows aseptic filling on prefilled syringes filling equipments available at most CDMO facilities . MARCH 2026 55
Slide 56: References
REFERENCES Slide 9: INTRAMUSCULAR IS THE STANDARD FOR EMERGENCY ADMINISTRATION 1. Brown JC, Tuuri RE, Akhter S, Guerra LD, Goodman IS, Myers SR, Nozicka C, Manzi S, Long K, Turner T, Conners GP, Thompson RW, Park E. Lacerations and Embedded Needles Caused by Epinephrine Autoinjector Use in Children.
Slide 57: References
REFERENCES Slide 16: THREE LAUNCH ZENEO ® APPLICATIONS IN ACTIVE DEVELOPMENT https://www.transparencymarketresearch.com/epilepsy - therapeutics - market.html 1. https://www.precedenceresearch.com/epilepsy - drug - market 2. https://www.datamintelligence.com/research - report/anaphylaxis - treatment
Slide 58: References
REFERENCES Slide 43 : ADAPTABILITY OF ZENEO ® PLATFORM OFFERS BROAD COMMERCIAL OPPORTUNITIES 1. Mehndiratta MM, Wadhai SA. International Epilepsy Day - A day notified for global public education & awareness . Indian J Med Res . 2015 7 2. Engel J Jr. Approaches to refractory epilepsy . Ann Indian Aca